Sanuwave Health (SNWV) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached a record $9.4 million, up 89% year-over-year and 31% sequentially, surpassing prior guidance, driven by strong UltraMIST system and consumables sales and higher average selling prices.

• Operating income improved to $2.0 million in Q3 2024, a $2.5 million improvement year-over-year, with the company becoming cash generative from operations even after interest expense.

• Net loss narrowed to $20.7 million for Q3 2024 from $23.7 million in Q3 2023, mainly due to changes in derivative liabilities, improved operating income, and a gain on debt extinguishment.

• The company completed a reverse stock split, note and warrant exchange, and closed a $10.3 million private placement, using proceeds to repay debt and simplify the capital structure.

• Wound care market trends toward evidence-based medicine and reimbursement align with company strengths in IP, reimbursement, and manufacturing.

Financial highlights

• Gross margin rose to 75.5%–76% in Q3 2024 from 71%–71.5% a year ago, aided by new contract manufacturing and pricing.

• Adjusted EBITDA was $2.1 million for Q3 2024, up from negative values in Q3 2023, reflecting operational improvements and non-recurring items.

• Cash at quarter-end was $3.3 million, with positive cash flow from operations of $1.7 million for the nine months.

• Net loss per share for Q3 2024 was $(6.49) (post-reverse split); accumulated deficit was $239 million as of September 30, 2024.

• Operating expenses increased to $5.1 million in Q3 2024, mainly from higher selling expenses.

Outlook and guidance

• Q4 2024 revenue guidance is $9.7–$10.5 million, representing 40–50% year-over-year growth; full-year 2024 revenue expected to exceed $32 million, up 57% year-over-year.

• Q4 gross margin expected to remain in the mid-70% range; operating expenses in Q4 expected to be flat versus Q3, with modest growth in 2025.

• Management plans to devote substantial resources to commercializing UltraMIST and PACE systems, requiring additional capital.

• There is substantial doubt about the ability to continue as a going concern without raising further capital.